NRAS and melanoma: In conclusion, upon stepwise investigations of efficacy in increasingly sophisticated models, the antitumor peptide RDP22 was found to offer a new approach in the treatment of MUG-Mel2, an NRAS mutated melanoma with a high demand for curative treatment.